<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983160</url>
  </required_header>
  <id_info>
    <org_study_id>PI12/01866</org_study_id>
    <nct_id>NCT04983160</nct_id>
  </id_info>
  <brief_title>Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial</brief_title>
  <official_title>Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial. Modulation of Cellular Mediators and Repair Endothelial Damage in Patients With Chronic Renal Disease Through Inhibition of Xanthine Oxidase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of inhibiting xanthine oxidase with&#xD;
      allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial&#xD;
      injury and vascular repair mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effect of inhibiting xanthine oxidase with&#xD;
      allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial&#xD;
      injury and vascular repair mechanisms, evaluating the plasma concentration of angiogenic&#xD;
      factors, microparticles of endothelial cells and the cell number circulating endothelial&#xD;
      progenitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2014</start_date>
  <completion_date type="Actual">April 29, 2016</completion_date>
  <primary_completion_date type="Actual">April 29, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating endothelial progenitor cells concentration and microparticles derived from endothelial cells</measure>
    <time_frame>Data collected after 4 weeks, 8 weeks and 12 weeks.</time_frame>
    <description>Effect of inhibiting xanthine oxidase with allopurinol in patients with CKD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of oxidative stress</measure>
    <time_frame>After patient visit (0 weeks, 4, 8 and 12 weeks)</time_frame>
    <description>Evaluated through quantification of oxygen-reactive species</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of micro inflammation</measure>
    <time_frame>After patient visit (0 weeks, 4, 8 and 12 weeks)</time_frame>
    <description>Evaluated through quantification of C-reactive protein, proinflammatory cytokines, CD14+ and CD16+ monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of endothelial dysfunction</measure>
    <time_frame>After patient visit (0 weeks, 4, 8 and 12 weeks)</time_frame>
    <description>Endothelium-dependant vasodilation in response to ischemia evaluated through changes in capillar flux using Doppler laser PeriFlux system 5000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Each visit (0 weeks, 4 weeks, 8 weeks and 12 weeks) for 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration ratio</measure>
    <time_frame>After patient visit (0 weeks, 4 weeks, 8 weeks and 12 weeks)</time_frame>
    <description>Estimated through MDRD-4 y Cockroft-Gault.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria / Proteinuria</measure>
    <time_frame>Daily, using first urine of the day as a sample.</time_frame>
    <description>Evaluated through albumin/creatinin ratio and protein/creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients willing and able to give informed consent for participation in the study&#xD;
&#xD;
          -  Ability to understand study procedures and to comply with it for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects of both sexes, the age range between 18 and 70 years old.&#xD;
&#xD;
          -  Serum uric acid above 7 mg / dl.&#xD;
&#xD;
          -  Estimated glomerular filtration rate by MDRD abbreviated formula less than 60 ml / min&#xD;
             / 1.73 m2 and above 15 ml / min / 1.73 m2.&#xD;
&#xD;
          -  Stability of renal function (serum creatinine increase without exceeding 50% in the&#xD;
             three months before the start of the study).&#xD;
&#xD;
          -  Clinically stable in terms of no hospitalizations of cardiovascular events in the 3&#xD;
             months before the study began.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drop active in the 60 days prior to study initiation.&#xD;
&#xD;
          -  Use of allopurinol within 60 days preceding baseline&#xD;
&#xD;
          -  Active infections within 30 days prior to baseline.&#xD;
&#xD;
          -  Patients with systemic inflammatory disease&#xD;
&#xD;
          -  Infection with HIV, Hepatitis C and Hepatitis B.&#xD;
&#xD;
          -  History of cancer within 5 years prior to the first dose of study medication&#xD;
&#xD;
          -  Chronic liver disease.&#xD;
&#xD;
          -  Immunosuppressive therapy.&#xD;
&#xD;
          -  Pregnant women, breastfeeding or planning to become pregnant.&#xD;
&#xD;
          -  Allergy or sensitive to allopurinol.&#xD;
&#xD;
          -  Addiction to drugs or alcohol, in the opinion of the investigator, may interfere with&#xD;
             compliance with study requirements.&#xD;
&#xD;
          -  Inability or unwillingness of the individual or legal guardian or representative to&#xD;
             give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Santamaría, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>allopurinol</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

